



ASX Announcement

23 November 2023

APPENDIX 3Y

Melbourne, Australia, 23 November 2023: Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company"), submits the Appendix 3Y of Dr Gregory Collier and Mr Matthew McNamara.

For enquiries, please contact

Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - avecho.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Avecho Biotechnology Limited	
ABN	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gregory Collier
Date of last notice	10 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Barwon Biotechnology Pty Ltd Dr Collier is a director and shareholder of the entity.
Date of change	22 November 2023
No. of securities held prior to change	Direct 5,990,465 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024. Indirect <i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i> 4,000,000 Fully Paid Ordinary Shares. <i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i> 3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026
Class	1. Fully Paid Ordinary Shares (AVE) 2. Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 5,833,333 8,749,999
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> \$0.006 per Fully Paid Ordinary Share Nil (free attaching Options)
No. of securities held after change	<p>Direct 5,990,465 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS)</p> <p>Indirect <i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i> 4,000,000 Fully Paid Ordinary Shares (AVE)</p> <p><i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i> 3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)</p> <p><i>Barwon Biotechnology Pty Ltd</i> <ol style="list-style-type: none"> 5,833,333 Fully Paid Ordinary Shares (AVE) 8,749,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) </p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of securities following shareholder approval at the General Meeting on 9 November 2023 on Resolution 4(b).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Avecho Biotechnology Limited
ABN	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Matthew Patrick McNamara
Date of last notice	31 May 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	MLAKS PTY LIMITED <M & L MCNAMARA S/F A/C> Mr McNamara is director and shareholder of the entity. He is also a beneficiary of the super fund.
Date of change	22 November 2023
No. of securities held prior to change	Indirect MLAKS PTY LTD <M & L MCNAMARA SUPER A/C> 3,993,644 Unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS)
Class	1. Fully Paid Ordinary Shares (AVE) 2. Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
Number acquired	1. 1,666,666 2. 2,499,999
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$0.006 per Fully Paid Ordinary Share 2. Nil (free attaching Options)

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Indirect <i>MLAKS PTY LIMITED <M & L McNAMARA SUPER A/C></i> <ul style="list-style-type: none"> 3,993,644 Unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS) 1,666,666 Fully Paid Ordinary Shares (AVE) 2,499,999 quoted options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities following shareholder approval at the General Meeting on 9 November 2023 on Resolution 4(a).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.